Product Name: MabThera/Rituxan [rituximab]
Date of Report: 6/1/2004
Phase: II
A randomized, double dummy controlled, parallel group study of the efficacy and safety of MabThera (rituximab) alone or in combination with either cyclophosphamide or methotrexate, in patients with rheumatoid arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 7/1/2005
Phase: II
A randomized, multifactorial, double-blind, parallel-group, dose-ranging study of the efficacy and safety of rituximab (MabThera/Rituxan) in combination with methotrexate in patients with active rheumatoid arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study to Assess the Safety and Efficacy of Retreatment with MabThera (rituximab) in Patients with Rheumatoid Arthritis Who Have Failed on anti-TNFα Therapy
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Study to Assess the Efficacy and Safety of Retreatment with MabThera (rituximab) in Patients with Active Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: 7/27/2005
Phase: III
A randomized, placebo-controlled, double-blind, mulitcenter study to evaluate the safety and efficacy of rituximab in combination with methotrexate in patients with active rheumatoid arthritis who have had an inadequate response to anti-TNF therapies.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of Retreatment With MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Combination With Methotrexate in Methotrexate-Naive Patients With Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: II
A Pharmacokinetic and Pharmacodynamic Study of MabThera (rituximab) Plus Methotrexate in Patients With Rheumatoid Arthritis (RA)
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
SMART Study: A Study of Re-treatment With MabThera (Rituximab) in Patients With Rheumatiod Arthritis Who Have Failed on Anti-TNF alpha therapy.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Failed on One Prior anti-TNF Therapy.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Quality of Life Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single anti-TNF Inhibitor.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a TNF-Blocker.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to anti-TNF Therapies.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Non-Comparative Study to Assess the Safety of MabThera (Rituximab) in Patients With Rheumatoid Arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of Re-Treatment With MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single anti-TNF Inhibitor.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to anti-TNF Agents.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to DMARD and/or anti-TNF Therapy.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: IV
A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had An Inadequate Response to a Single anti-TNF Inhibitor.
Product Name: MabThera/Rituxan [rituximab]
Date of Report: To be Published
Phase: III
R.A. SCORE Study: A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis and Inadequate Response to Methotrexate.
Product Name: ocrelizumab
Date of Report: To be Published
Phase: II
A Study of Ocrelizumab in Patients with Rheumatoid Arthritis
Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate.
Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to anti-TNF-alpha Therapy.
Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab in Combination With Methotrexate in Patients with Rheumatoid Arthritis Who Are Naive to Methotrexate.
Product Name: ocrelizumab
Date of Report: To be Published
Phase: III
A Study of Ocrelizumab Given as a Single or Dual Infusion in Patients With Rheumatoid Arthritis Who Have An Inadequate Response to Methotrexate
Product Name: P38 Inhibitor (4)
Date of Report: To be Published
Phase: II
A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
Product Name: P38 Inhibitor (4)
Date of Report: 5/2/2008
Phase: II
A Study of P38 Inhibitor (4) Monotherapy in Patients with Active Rheumatoid Arthritis
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients with Moderate to Severe Active Rheumatoid Arthritis
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients with Moderate to Severe Active Rheumatoid Arthritis
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients with Moderate to Severe Active Rheumatoid Arthritis
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients with Active Rheumatoid Arthritis
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients with Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy.
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study of Actemra (Tocilizumab) in Patients Completing Treatment in WA17822
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study of Actemra (Tocilizumab) in Patients Completing Treatment in Actemra Core Studies
Product Name: tocilizumab
Date of Report: To be Published
Phase: I
A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study of Tocilizumab in Combination With Methotrexate in Patients With Moderate to Severe Rheumatoid Arthritis.
Product Name: tocilizumab
Date of Report: To be Published
Phase: III
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis.
